We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
Bristol Myers Squibb (BMY - Free Report) closed at $59.16 in the latest trading session, marking a +0.44% move from the prior day. This change outpaced the S&P 500's 0.4% gain on the day. Elsewhere, the Dow gained 0.13%, while the tech-heavy Nasdaq added 0.45%.
Heading into today, shares of the biopharmaceutical company had lost 5.12% over the past month, outpacing the Medical sector's loss of 5.26% and lagging the S&P 500's loss of 1.38% in that time.
Bristol Myers Squibb will be looking to display strength as it nears its next earnings release, which is expected to be October 26, 2023. The company is expected to report EPS of $1.82, down 8.54% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $10.96 billion, down 2.33% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $7.43 per share and revenue of $44.71 billion, which would represent changes of -3.51% and -3.14%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Bristol Myers Squibb. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.64% lower. Bristol Myers Squibb is currently a Zacks Rank #3 (Hold).
In terms of valuation, Bristol Myers Squibb is currently trading at a Forward P/E ratio of 7.93. For comparison, its industry has an average Forward P/E of 16.9, which means Bristol Myers Squibb is trading at a discount to the group.
It is also worth noting that BMY currently has a PEG ratio of 1.57. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BMY's industry had an average PEG ratio of 2.13 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 93, which puts it in the top 37% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
Bristol Myers Squibb (BMY - Free Report) closed at $59.16 in the latest trading session, marking a +0.44% move from the prior day. This change outpaced the S&P 500's 0.4% gain on the day. Elsewhere, the Dow gained 0.13%, while the tech-heavy Nasdaq added 0.45%.
Heading into today, shares of the biopharmaceutical company had lost 5.12% over the past month, outpacing the Medical sector's loss of 5.26% and lagging the S&P 500's loss of 1.38% in that time.
Bristol Myers Squibb will be looking to display strength as it nears its next earnings release, which is expected to be October 26, 2023. The company is expected to report EPS of $1.82, down 8.54% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $10.96 billion, down 2.33% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $7.43 per share and revenue of $44.71 billion, which would represent changes of -3.51% and -3.14%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Bristol Myers Squibb. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.64% lower. Bristol Myers Squibb is currently a Zacks Rank #3 (Hold).
In terms of valuation, Bristol Myers Squibb is currently trading at a Forward P/E ratio of 7.93. For comparison, its industry has an average Forward P/E of 16.9, which means Bristol Myers Squibb is trading at a discount to the group.
It is also worth noting that BMY currently has a PEG ratio of 1.57. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BMY's industry had an average PEG ratio of 2.13 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 93, which puts it in the top 37% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.